Skip to content
MarketScale
‹ Back to IndustriesSciences

The Industry That is Depending on Science and Regulation to Grow

Yuran Li, Director of MS Commercial Strategies at Alternative Biomedical Solutions, plays a pivotal role in cannabis testing and method development, addressing the complexities of cannabis as a consumable product. As more states legalize cannabis, rigorous testing is necessary to ensure safety and proper labeling due to the plant's tendency to absorb harmful substances like pesticides and heavy metals.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Jason Claybrook · Alternative Biomedical SolutionsCannabinoidCannabisCannabis Testing
Share
The Industry That is Depending on Science and Regulation to Grow

Key takeaways

01

Alternative Biomedical Solutions is a pioneer in cannabis method development and testing.

02

Yuran Li emphasizes the importance of rigorous cannabis testing due to its unique absorption of pesticides and heavy metals.

03

Different states have varied laws on cannabis sales, making it essential to understand individual state regulations.

Get featured

Want to get featured in MarketScale Sciences?

Create a free MarketScale workspace and get your company's expertise featured across our Sciences coverage. No credit card, no demo required.

Start free

Yuran Li, Director, MS Commercial Strategies, Alternative Biomedical Solutions (ABS), is a biochemist by training. Still, his fascinations with physics, math, and probability have led him down some interesting paths, including some stints in the professional poker world. Lucky for ABS, he chose the science route.

Cannabis is a schedule 1 drug classification by the U.S. Federal government. As more and more states legalize it, there is a growing need for reliable testing to ensure the safety and potency of cannabis products. ABS is one of the pioneers in cannabis method development and testing. Li spoke with Jason Claybrook on some of ABS’s activities surrounding Cannabis.

Any product that people consume goes through testing to ensure their safety. “Cannabis is unique in that it’s ultimately a weed,” Li said. And it can prove quite a challenge to cultivate because the plant can soak up a lot of pesticides and other elements used for pest control. “Additionally, the Cannabis plant itself also uptakes quite a lot of heavy metals, things like arsenic and lead.” Accumulation of these pollutants can harm humans, so accurate testing is essential.

Some of the testing ABS does on Cannabis is to look for micro toxins, like mold and soil pollutants. And from a marketing and regulatory standpoint, they test for potency. In some cases, testing can help ensure that a strain grown for CBD does not contain THC. One challenge Li cautioned is every state has different guidelines, and it is essential to understand the laws governing each state where Cannabis sales are allowed.

Another aspect of lab testing that is becoming more and more important for Cannabis is label testing. As with craft beers and whiskey, labels need to back up their product’s claims. Testing ensures the strain offered on the label is the strain received by the consumer.

Breaking through ‘Pilot Purgatory’ in Innovating New Solutions

Is Cryptocurrency and Its Tech Infrastructure Ready for a Revolution?

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

JC
Jason Claybrook

Follow Sciences Insights

Get new expert content in your inbox.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Sciences Insights

Pharma supplier diversification means little if every supplier uses the same airport

Pharma supplier diversification means little if every supplier uses the same airport

Biocair's Patrick Wohl argues in Pharmaceutical Commerce that life sciences firms must map airports, sea lanes, customs gateways and carriers alongside suppliers. Suppliers spread across countries can still share one air hub. The fix he describes is pre-qualified alternate routes and continuous review, with clinical trial shipments and cold-chain medicines the first cargo exposed when a corridor closes.

  • 01A supplier base spread across several countries can still be a single point of failure if every shipment routes through one airport hub or corridor; the sharper question for a logistics provider is which hubs each qualified lane actually depends on.
  • 02Gartner data cited by MD+DI gives a benchmark: 42% of procurement leaders rank supply disruption as their organization's top risk, with geopolitical issues including tariffs and regulatory changes ranking third.
  • 03A route map ages fast. Pharmaceutical Commerce published the mapping argument on July 24 and was reporting fresh Red Sea and Iran-related freight risk for pharma lanes by Aug. 10, which is the case for treating mapping as a recurring review rather than a project.

Sep 17, 2026

Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply

Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply

Resilience and Eli Lilly are investing $750 million to expand KwikPen injectable device production at Resilience's Cincinnati-region manufacturing facility, expected to create 400 high-skilled jobs and reach full operations by early 2027. The partnership builds on their collaboration since 2023, which has already produced over 150 million doses of Lilly medications for the U.S. market.

  • 01$750 million investment to expand Resilience's Ohio manufacturing capacity for Eli Lilly's KwikPen injectable device production
  • 02400 new high-skilled jobs expected in Cincinnati region, with full operations by early 2027
  • 03Partnership has already produced over 150 million doses of Lilly medications for the U.S. market since 2023

Sep 14, 2026

ENEOS ran an AI controller on a distillation column for 35 days and cut steam use 40%

ENEOS ran an AI controller on a distillation column for 35 days and cut steam use 40%

ENEOS Materials and Yokogawa ran an autonomous AI controller on a butadiene distillation column for 35 days and cut steam use 40%. It’s a real operations proof point. It also puts integration and governance gaps front and center.

  • 01A 35-day closed-loop run is a stronger autonomy proof point than a demo, it forces plants to prove handover, fallback, and KPIs over real feed and operating swings.
  • 02Steam reduction claims are compelling, but procurement and ops teams should pin vendors to baselines, operating envelopes, and how off-spec avoidance is measured.
  • 03Agentic AI is showing up as “work management” and “shift checklist” agents before it replaces control engineers, which shifts requirements toward clean, permissioned data access.

Sep 13, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Experts

YL
Yuran Li

Director, MS Commercial Strategies

Alternative Biomedical Solutions (ABS)

Yuran Li is a biochemist by training with a fascination for physics, math, and probability, and has had professional experience in the poker world. At ABS, he plays a key role in cannabis method development and testing.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512